化工社化工社 化学情報印刷レポート · 研究参考用
Acetate → Bupropion
関与物質
| 役割 | 名称 | HCID | 仕込み量 |
|---|---|---|---|
| 反応物 | Acetate | HCID 175 | — |
| 反応物 | Phosphate | HCID 1061 | — |
| 反応物 | Bupropion Hydrochloride | HCID 62884 | — |
| 反応物 | Bupropion Hydrobromide | HCID 11984562 | — |
| 生成物 | Bupropion | HCID 444 | — |
反応手順
The dissolution of bupropion HBr formulations according to the invention were assessed in three USP-3 media, i.e., SGF pH 1.2, Acetate Buffer pH 4.5 and Phosphate Buffer pH 6.8 over a period of 16 hours. These results are contained in FIG. 66. Particularly Bupropion HBr XL 348 mg tablets (final), Lot # Bup-HBr-XL-012-5; Wellbutrin XL 300 mg tablets (final), Lot # 05A116; Bupropion HBr XL 348 mg tablets ECl Lot # Bup-HBr-XL-012-5 (EC 32 mg wg) and Wellbutrin XL 300 mg tablets (EC10-Lot # 05D047 were assessed in SGF media pH 1.2 for 2 hours, Acetate Buffer pH 4.5 for 2 hours, and Phosphate Buffer SIF pH 6.8 for a total of 10 hours. The results are contained in the FIG. 66-68.
情報源と証拠
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| 特許番号 | US07563823B2 |
| 出典データセット | uspto-grants-2009_07 |
| ORD ID | ord-40e1bbce3083436c940deac123c8d01f |
| 出典メモ | uspto-grants-2009_07 |